Insights

Innovative Genetic Focus BridgeBio specializes in developing treatments for genetic diseases with significant unmet needs, presenting opportunities to collaborate with healthcare providers seeking novel therapies in rare disorder markets.

Recent Clinical Milestones The company has demonstrated substantial clinical success, notably in reducing all-cause mortality in ATTR-CM populations, indicating advanced pipeline candidates that can be marketed to specialty clinics and academic centers.

Strategic Funding and Expansion With a robust funding profile of 500 million dollars and ongoing employee growth, BridgeBio is positioned to expand its therapeutic portfolio and establish partnerships that capitalize on its innovative pipeline.

Engagement at Major Conferences Participation in prominent conferences like AHA and UBS emphasizes the company's active engagement with healthcare professionals, creating opportunities for targeted outreach and educational collaborations.

Partnership and Investment Potential The involvement of institutional investors such as the Teacher Retirement System of Texas alongside ongoing research advancements suggests strong potential for strategic alliances, licensing deals, and investor-driven sales opportunities.

BridgeBio Tech Stack

BridgeBio uses 8 technology products and services including SAS/GRAPH, GitHub, SAP HANA, and more. Explore BridgeBio's tech stack below.

  • SAS/GRAPH
    Business Intelligence
  • GitHub
    Communication And Collaboration
  • SAP HANA
    Database Management
  • BetterUp
    Human Capital Management
  • Lumit
    Restaurant Reservations
  • Yoast SEO
    Search Engines
  • Apache Subversion
    Source Code Management
  • SigmaPlot
    Visualisation Software

Media & News

BridgeBio's Email Address Formats

BridgeBio uses at least 1 format(s):
BridgeBio Email FormatsExamplePercentage
First.Last@bridgebio.comJohn.Doe@bridgebio.com
84%
FL@bridgebio.comJD@bridgebio.com
8%
FLast@bridgebio.comJDoe@bridgebio.com
5%
Last@bridgebio.comDoe@bridgebio.com
3%

Frequently Asked Questions

Where is BridgeBio's headquarters located?

Minus sign iconPlus sign icon
BridgeBio's main headquarters is located at 421 Kipling St Palo Alto, California US. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is BridgeBio's stock symbol?

Minus sign iconPlus sign icon
BridgeBio is a publicly traded company; the company's stock symbol is BBIO.

What is BridgeBio's official website and social media links?

Minus sign iconPlus sign icon
BridgeBio's official website is bridgebio.com and has social profiles on LinkedIn.

What is BridgeBio's SIC code NAICS code?

Minus sign iconPlus sign icon
BridgeBio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BridgeBio have currently?

Minus sign iconPlus sign icon
As of October 2025, BridgeBio has approximately 806 employees across 6 continents, including North AmericaEuropeAsia. Key team members include Ceo And Founder: N. K.Chief Executive Officer At Qed Therapeutics Oncology And Chief Commercial Officer At Bridgebio: M. O.Ceo Of Gene Therapy: E. D.. Explore BridgeBio's employee directory with LeadIQ.

What industry does BridgeBio belong to?

Minus sign iconPlus sign icon
BridgeBio operates in the Biotechnology Research industry.

What technology does BridgeBio use?

Minus sign iconPlus sign icon
BridgeBio's tech stack includes SAS/GRAPHGitHubSAP HANABetterUpLumitYoast SEOApache SubversionSigmaPlot.

What is BridgeBio's email format?

Minus sign iconPlus sign icon
BridgeBio's email format typically follows the pattern of First.Last@bridgebio.com. Find more BridgeBio email formats with LeadIQ.

How much funding has BridgeBio raised to date?

Minus sign iconPlus sign icon
As of October 2025, BridgeBio has raised $500M in funding. The last funding round occurred on Feb 25, 2025 for $500M.

When was BridgeBio founded?

Minus sign iconPlus sign icon
BridgeBio was founded in 2014.

BridgeBio

Biotechnology ResearchCalifornia, United States501-1000 Employees

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases.

Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.

BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity.

Section iconCompany Overview

Headquarters
421 Kipling St Palo Alto, California US
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
BBIO
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
501-1000

Section iconFunding & Financials

  • $500M

    BridgeBio has raised a total of $500M of funding over 14 rounds. Their latest funding round was raised on Feb 25, 2025 in the amount of $500M.

  • $1M$10M

    BridgeBio's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $500M

    BridgeBio has raised a total of $500M of funding over 14 rounds. Their latest funding round was raised on Feb 25, 2025 in the amount of $500M.

  • $1M$10M

    BridgeBio's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.